Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

T R D J Radstake, M Svenson, A M Eijsbouts, F H J van den Hoogen, C Enevold, P L C M van Riel, K Bendtzen

    335 Citationer (Scopus)

    Abstract

    Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).
    OriginalsprogEngelsk
    TidsskriftAnnals of the Rheumatic Diseases
    Vol/bind68
    Udgave nummer11
    Sider (fra-til)1739-45
    Antal sider7
    ISSN0003-4967
    DOI
    StatusUdgivet - 1 nov. 2009

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis'. Sammen danner de et unikt fingeraftryk.

    Citationsformater